WebLaurikka-Routti, M., & Haukkamaa, M. (1992). A contraceptive subdermal implant releasing the progestin ST-1435 - ovarian-function, bleeding patterns, and side-effects. Fertility and …
Did you know?
Web1 Dec 1992 · Laurikka-Routti, M. Haukkamaa, O. Heikinheimo, A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipid and serum chemistry Contraception 42: (1990) 111-120 13. WebThe progest in ST 1435, used parenterally for contraception or progestin therapy, had no adverse effects on serum lipids, blood pressure, or body weight, which are known to be risk factors for coronary artery disease. Objective: To study the changes in serum lipids, serum chemistry, blood pressure, and body weight in long-term users of subcutaneous …
WebFinding the cause of the infection requires analyzing certain samples, since the doctor’s eye cannot solely distinguish the cause of the infection, Laurikka-Routti explains. It is … WebM Laurikka-Routti 1 , M Haukkamaa, O Heikinheimo. Affiliation 1 Department of Medical Chemistry, University of Helsinki, Finland. PMID: 2387151 DOI: 10.1016/0010 …
Web1 Oct 1992 · M. Laurikka-Routti, M. Haukkamaa, O. Heikinheimo A contraceptive vaginal ring releasing ethinyl estradiol and the progestin ST-1435: bleeding control, serum steroid concentrations, serum lipids and serum chemistry Contraception, 42 ( 1990), pp. 111 - 120 View PDF View article View in Scopus Google Scholar 10. WebLaurikka-Routti, Marjut ; Haukkamaa, Maija. / A contraceptive subdermal implant releasing the progestin ST-1435 - ovarian-function, bleeding patterns, and side-effects.Julkaisussa: Fertility and Sterility : official journal of the American Fertility Society . 1992 ; Vuosikerta 58.Sivut 1142-1147.
WebDOI: 10.1016/S0010-7824(01)00294-3 Corpus ID: 8692342; Mechanisms that explain the contraceptive action of progestin implants for women. @article{Croxatto2002MechanismsTE, title={Mechanisms that explain the contraceptive action of progestin implants for women.}, author={Horacio B. Croxatto}, …
WebMarjut Laurikka-Routti Naistentautien ja synnytysten erikoislääkäri Näytä vapaat ajat Hinnasto Esittely Hoidan laajalti gynekologisia vaivoja ja asioita: vaihdevuosia, ehkäisyä, … siue sweatshirtsWebMarjut Laurikka-Routti, Maija Haukkamaa, Pekka Lähteenmäki. Department of Obstetrics and Gynecology; Research output: Contribution to journal › Article › Scientific › peer-review. Overview; Original language: English: Journal: Fertility and Sterility : official journal of the American Fertility Society : Volume: 58: Pages (from-to) siue textbook rentalWebDOI: 10.1016/0010-7824(81)90115-3 Corpus ID: 72256207; Contraception with subcutaneous capsules containing ST-1435. Pituitary and ovarian function and plasma levels of ST-1435 siue technical servicesWeb1 Aug 1999 · Nestorone ® (NES, previously known as ST-1435) is an orally inactive progestin, currently in phase II clinical contraceptive trials using implants, vaginal rings, and intracervical or transdermal administration ( Kurunmäki et al., 1984; Laurikka-Routti et al., 1990; Haukkamaa et al., 1991 ). siue thanksgiving break 2021WebLaurikka-Routti. LKT, naistentautien ja synnytysten erikoislääkäri. Asiakasarvio 9.7. 24kk keskiarvo, kun vastauksia yli 25 kpl. Siirry verkkoajanvaraukseen. Marjut Laurikka … siue textbook services emailWeb1 Nov 1992 · Laurikka-Routti M 1. Author information. Affiliations. 1 author. 1. City Maternity Hospital, Helsinki, Finland. Obstetrics and Gynecology, 01 Nov 1992, 80(5): 855-859 … siue thanksgiving breakWebThe progest in ST 1435, used parenterally for contraception or progestin therapy, had no adverse effects on serum lipids, blood pressure, or body weight, which are known to be … siue textbooks